These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21925957)

  • 1. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
    Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
    Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
    Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is prostate-specific antigen percentage decrease predictive of clinical outcome after permanent iodine-125 interstitial brachytherapy for prostate cancer?
    Paoluzzi M; Mignogna M; Lorenzini E; Valent F; Fontana N; Pinzi N; Repetti F; Ponchietti R
    Brachytherapy; 2012; 11(4):277-83. PubMed ID: 22137870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
    Peters CA; Stock RG; Blacksburg SR; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
    Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
    BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
    Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.